1. Ibrutinib-induced pulmonary angiotensin-converting enzyme activation promotes atrial fibrillation in rats
- Author
-
Sen Yan, Wei Xu, Ning Fang, Luyifei Li, Ning Yang, Xinbo Zhao, Hongting Hao, Yun Zhang, Qian Liang, Zhiqi Wang, Yu Duan, Song Zhang, Yongtai Gong, and Yue Li
- Subjects
Pharmacology ,Natural sciences ,Biological sciences ,Physiology ,Science - Abstract
Summary: The molecular mechanism of ibrutinib-induced atrial fibrillation (AF) remains unclear. We here demonstrate that treating rats with ibrutinib for 4 weeks resulted in the development of inducible AF, left atrial enlargement, atrial fibrosis, and downregulation of connexin expression, which were associated with C-terminal Src kinase (CSK) inhibition and Src activation. Ibrutinib upregulated angiotensin-converting enzyme (ACE) protein expression in human pulmonary microvascular endothelial cells (HPMECs) by inhibiting the PI3K-AKT pathway, subsequently increasing circulating angiotensin II (Ang II) levels. However, the expression of ACE and Ang II in the left atria was not affected. Importantly, we observed that perindopril significantly mitigated ibrutinib-induced left atrial remodeling and AF promotion by inhibiting the activation of the ACE and its downstream CSK-Src signaling pathway. These findings indicate that the Ibrutinib-induced activation of the ACE contributes to AF development and could serve as a novel target for potential prevention strategies.
- Published
- 2024
- Full Text
- View/download PDF